Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | IAPP | P10997 | 4/20 | 0.51 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.50 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.50 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.50 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1450886 | 0.83 | NPSR1 (0.57) | NPSR1PTGER4PTGER3PTGER2PTGER1 | |
| SCHEMBL30873948 | 0.83 | NPSR1 (0.57) | NPSR1PTGER4PTGER3PTGER2PTGER1 | |
| SCHEMBL323867 | 0.82 | NPSR1 (0.61) | NPSR1PTGER4PTGER3PTGER2PTGER1 | |
| SCHEMBL29843936 | 0.82 | NPSR1 (0.61) | NPSR1PTGER4PTGER3PTGER2PTGER1 | |
| SCHEMBL11125140 | 0.81 | FFAR1 (0.49) | NPSR1IAPPPTGER4PTGER3PTGER2 | |
| SCHEMBL5106925 | 0.81 | PTGS2 (0.56) | PTGER4PTGER3PTGER2PTGER1ALDH1A1 | |
| SCHEMBL244943 | 0.81 | IAPP (0.70) | NPSR1IAPPPTGER4PTGER3PTGER2 | |
| SCHEMBL29430565 | 0.81 | PTGS2 (0.56) | PTGER4PTGER3PTGER2PTGER1ALDH1A1 | |
| Water SCHEMBL10936872 | 0.81 | NPSR1 (0.59) | NPSR1PTGER4PTGER3PTGER2PTGER1 | |
| SCHEMBL30485631 | 0.81 | IAPP (0.70) | NPSR1IAPPPTGER4PTGER3PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3661901-B1 | SYNTHESIS OF GLYCOLS VIA TRANSFER HYDROGENATION OF ALPHA-FUNCTIONAL ESTERS WITH ALCOHOLS | EASTMAN CHEM CO (US) | 2023-12-06 | — | — | EP | disclosed |
| US-10266467-B2 | Synthesis of glycols via transfer hydrogenation of alpha-functional esters with alcohols | EASTMAN CHEMICAL COMPANY (US) | 2019-04-23 | — | — | US | disclosed |
| US-20190039978-A1 | SYNTHESIS OF GLYCOLS VIA TRANSFER HYDROGENATION OF ALPHA-FUNCTIONAL ESTERS WITH ALCOHOLS | EASTMAN CHEMICAL COMPANY (US) | 2019-02-07 | — | — | US | disclosed |
| EP-1448514-A1 | NOVEL ALPHA-OXYGENATED OR ALPHA-THIOLATED CARBOXYLIC ACID PHENETHYLAMIDE DERIVATIVES | Syngenta Participations AG (CH) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003042168-A1 | NOVEL α-OXYGENATED OR α-THIOLATED CARBOXYLIC ACID PHENETHYLAMIDE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190039978-A1 | SYNTHESIS OF GLYCOLS VIA TRANSFER HYDROGENATION OF ALPHA-FUNCTIONAL ESTERS WITH ALCOHOLS | ADH1A, ADH1C, ADH5 | NPSR1 4144/4885IAPP 2444/4885PTGER4 667/4885 |
| US-10266467-B2 | Synthesis of glycols via transfer hydrogenation of alpha-functional esters with alcohols | ADH1A, ADH1C, ADH5 | NPSR1 4144/4885IAPP 2444/4885PTGER4 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.